Surface Oncology (NASDAQ:SURF) is up 13.8% postmarket after the FDA cleared Investigational New Drug applications for antibody candidates SRF617 and SRF388.
It’s planning to initiate clinical trials to advance both the programs.
The company’s also moving forward on a
restructuring that will cut the workforce by about 35%, and says with
that, cash and equivalents are projected to fund the company through
2022.
SRF617 targets CD39; SRF388 targets IL-27.
https://seekingalpha.com/news/3534966-surface-oncologyplus-14-fda-clears-two-inds
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.